Cardiovascular risk factors

Nephrology

Volumn 10, Issue SUPP. 5, 2005, Pages

  Walker, Rob ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CREATININE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; HEART INFARCTION; HEMODIALYSIS; HUMAN; KIDNEY TRANSPLANTATION; META ANALYSIS; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33845603669     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00507.x     Document Type: Review

References (15)

1. ANZDATA. ANZDATA Registry Report 2004. Adelaide: Australia and New Zealand Dialysis and Transplant Registry, 2004.
2. Foley RN, Parfrey PS, Sanak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis 1998; 32 (Suppl 3): S112-S119.
3. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol. 1999; 19: 187-95.
4. La Rosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomised controlled trials. JAMA 1999; 282: 2340-6.
5. Holdass H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre randomised placebo controlled trial. Lancet 2003; 361: 2024-31.
6. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J. Med. 2005; 353: 238-48.
7. Tonelli M, Moye L, Sacks FM et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann. Intern. Med. 2003; 138: 98-104.
8. Tonelli M, Isles C, Curhan GC et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004; 110: 1557-63.
9. Tonelli M, Collins D, Robins S et al. The Veterans' Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) investigators. Kidney Int. 2004; 66: 1123-30.
10. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
11. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am. J. Kidney Dis 1998; 32 (5 Suppl 3): S142-S146.
12. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am. J. Kidney Dis 1998; 32: 853-906.
13. National Cholesterol Education Program Adult Treatment Panel II. Summary of the second report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 1993; 269: 3015-23.
14. Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur. Heart J. 1998; 19: 1434-503.
15. Nutrition and Metabolism Advisory Committee. Guide for the use of lipid-lowering drugs in adults. Position statement prepared by the nutrition and Metabolism Advisory Committee for the National Heart Foundation of Australia. Melbourne: National Heart Foundation, 1998.